Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223203 · ClinicalTrials.gov registry record · Phase 3
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
A Phase 3 study of Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy and hATTR-PN, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT07223203 is a Phase 3 study of Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy and hATTR-PN that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 125 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07223203, a Phase 3 study of Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy and hATTR-PN, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Conditions Studied
Interventions
- DRUG Nucresiran
- DRUG Vutrisiran
Study Locations (1)
Massachusetts
- Clinical Trial Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2026-01-16 |
| Est. Completion | 2031-06-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07223203
The ClinicalTrials.gov registry entry for NCT07223203 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy appearing as the primary indexed condition, and to 2 interventions - of which Nucresiran is the first listed.
NCT07223203 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07223203 about?
NCT07223203 is a clinical study titled "TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy". The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect t...
What is the current status of trial NCT07223203?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2026-01-16. Estimated completion is 2031-06-12.
What conditions does trial NCT07223203 study?
This clinical trial studies the following conditions: Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN.
What interventions are being tested in trial NCT07223203?
The interventions under investigation include: Nucresiran (DRUG), Vutrisiran (DRUG).
Who is sponsoring clinical trial NCT07223203?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223203 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
All registered trials for this condition
hATTR-PN
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.